NT5E and cancer: Reduction in the percentage of CD4+ T cells expressing PD-1, CD73, CD160, or LAG3 by LYC-54143 was observed in differentiated human Type 17 T cells using PBMCs from cancer patients as well as healthy donors (Figs. S3G and H).